Holds 2 active US DMFs and 2 valid CEPs for erythromycin, filing since 2009. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds one active US DMF for erythromycin, filing since 2019. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 19 markets.
Holds 3 active US DMFs for erythromycin, filing since 2020. Its 2023 FDA inspection closed as NAI, and its GMP is recognised in 3 markets.
Holds one active US DMF for erythromycin, filing since 2020. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds one active US DMF for erythromycin, filing since 2020. Its 2026 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF for erythromycin, filing since 2019. Its 2025 FDA inspection closed as VAI.
Holds 2 active US DMFs for erythromycin, filing since 2013.
Holds one active US DMF for erythromycin, filing since 2013.
Holds 3 active US DMFs for erythromycin, filing since 2006. Its 2024 FDA inspection closed as OAI, and its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
This page filters the worldwide Erythromycin manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free